Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials

Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial

(2018) John R. Perfect et al.   MYCOSES

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

(2016) Thomas F. Patterson et al.   CLINICAL INFECTIOUS DISEASES

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients

(2016) Frederic Tissot et al.   HAEMATOLOGICA

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

(2016) Johan A Maertens et al.   LANCET

Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

(2016) Francisco M Marty et al.   LANCET INFECTIOUS DISEASES

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients

(2016) Frederic Tissot et al.   HAEMATOLOGICA

Multicenter Study of Isavuconazole MIC Distributions and Epidemiological Cutoff Values for Aspergillus spp. for the CLSI M38-A2 Broth Microdilution Method

(2013) A. Espinel-Ingroff et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroSusceptibility of Aspergillus fumigatus to Isavuconazole: Correlation with Itraconazole, Voriconazole, and Posaconazole

(2013) Lea Gregson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds

(2013) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance

(2013) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001–2006: Overview of the Transplant‐Associated Infection Surveillance Network (TRANSNET) Database

(2010) Dimitrios P. Kontoyiannis et al.   CLINICAL INFECTIOUS DISEASES

Factors Associated with Mortality in Transplant Patients with Invasive Aspergillosis

(2010) John W. Baddley et al.   CLINICAL INFECTIOUS DISEASES

Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplant‐Associated Infection Surveillance Network (TRANSNET)

(2010) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Fungal Infections in Leukemia Patients: How Do We Prevent and Treat Them?

(2010) Konstantinos Leventakos et al.   CLINICAL INFECTIOUS DISEASES

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

(2008) Ben De Pauw et al.   CLINICAL INFECTIOUS DISEASES

EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia–forming moulds

(2008)   CLINICAL MICROBIOLOGY AND INFECTION